Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd announced its participation at the Pitt Street Research Life Sciences Conference 2024, with Executive Chairman Dr. Paul MacLeman set to discuss the Phase 2a/b dengue fever trial of their lead drug ISLA-101, and detail the company’s plans to acquire the antiviral molecule, galidesivir. The Australian company, specializing in repurposing drugs for infectious diseases, also hinted at the potential for a Priority Review Voucher from the FDA, which could fast-track approvals or be sold on the secondary market. Investors are encouraged to adopt a paperless approach by registering with the Company’s share registry.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.
